Similar Articles
231 Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation
232 Lipid-lowering agents in the management of nonalcoholic fatty liver disease
233 Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome
234 Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease
235 FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation
236 Targeting inflammation in diabetes: Newer therapeutic options
237 Apolipoprotein C3 (-455T>C) polymorphism confers susceptibility to nonalcoholic fatty liver disease in the Southern Han Chinese population
238 Nonalcoholic fatty liver disease and vascular disease: State-of-the-art
239 Nonalcoholic fatty liver disease: A comprehensive review of a growing epidemic
240 Management of nonalcoholic fatty liver disease: An evidence-based clinical practice review
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA